Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

Pfizer Recalls Blood Pressure Drug Accuretic in UK Due to Nitrosamine Risk
Pfizer Recalls Blood Pressure Drug Accuretic in UK Due to Nitrosamine Risk
Pfizer has recalled a single batch of its blood pressure drug, Accuretic (quinapril HCl/hydrochlorothiazide), in the UK following the detection of a nitrosamine contaminant, N-nitroso-quinapril, a...
FDA Delays Decision on Merck’s Pediatric Pneumococcal Vaccine
FDA Delays Decision on Merck’s Pediatric Pneumococcal Vaccine
The FDA has pushed back its decision date for Merck’s supplemental Biologics License Application (sBLA) for its 15-valent pneumococcal conjugate vaccine for pediatric patients by three months to...
NICE Recommends Evenity for Patients With Severe Osteoporosis
NICE Recommends Evenity for Patients With Severe Osteoporosis
The UK’S National Institute for Health and Care Excellence (NICE) has recommended Amgen’s Evenity (romosozumab) for use by the National Health Service (NHS) for the treatment of postmenopausal...
Merck’s COVID-19 Drug Lagevrio Shows Promise in Phase 3 Study
Merck’s COVID-19 Drug Lagevrio Shows Promise in Phase 3 Study

Merck has released positive results from a phase 3 study of its investigational oral antiviral COVID-19 drug Lagevrio (molnupiravir).

FDA Approves Oral Testosterone Replacement Therapy for Hypogonadism
FDA Approves Oral Testosterone Replacement Therapy for Hypogonadism
Estosterone undecanoate (Tlando; Antares Pharma, Inc) is indicated as testosterone replacement therapy for conditions associated with a deficiency or absence of endogenous testosterone in adult pat...
Reversing hearing loss with regenerative therapy
Reversing hearing loss with regenerative therapy

Most of us know someone affected by hearing loss, but we may not fully appreciate the hardships that lack of hearing can bring. 

FDA Approves Triumeq PD for Children With HIV
FDA Approves Triumeq PD for Children With HIV
The FDA has approved a new drug application (NDA) for a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir, and lamivudine treatment (Triumeq PD; ViiV Healthcare...
FDA Grants Fast Track Designation to ASC Therapeutics’ Gene Therapy for Hemophilia A
FDA Grants Fast Track Designation to ASC Therapeutics’ Gene Therapy for Hemophilia A

The U.S. Food and Drug Administration granted Fast Track designation for ASC Therapeutics’ ASC618, a second-generation gene therapy of hemophilia A.

Vuity From Allergan
Vuity From Allergan

The FDA has approved pilocarpine hydrochloride ophthalmic solution 1.25% (Vuity, Allergan, an AbbVie company) to treat presbyopia in adults.

Genentech: Phase 3 Study of Immunotherapy in ES-SCLC Fails to Meet Co-primary Endpoint
Genentech: Phase 3 Study of Immunotherapy in ES-SCLC Fails to Meet Co-primary Endpoint
The phase 3 SKYSCRAPER-02 study, which evaluated the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as an initi...
Baricitinib Produces Significant Hair Regrowth in Adults With Severe Alopecia Areata
Baricitinib Produces Significant Hair Regrowth in Adults With Severe Alopecia Areata
Baricitinib (Olumiant; Eli Lilly and Incyte ) was found to produce significant hair regrowth on the scalp, eyelashes, and eyebrows of adults with severe alopecia areata. ...
FDA Grants Priority Review to Futibatinib for Metastatic Cholangiocarcinoma
FDA Grants Priority Review to Futibatinib for Metastatic Cholangiocarcinoma
The FDA has granted priority review to a New Drug Application (NDA) for Taiho Oncology, Inc’s futibatinib (TAS-120) in the treatment of patients with previously treated locally advanced or metas...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand